Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
poseltinib + lenalidomide + glofitamab
- Development stage
- Unknown
- Lead developer
- NOBO Medicine
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Poseltinib + lenalidomide + glofitamab (also known as the GPL regimen or Project 201) is an investigational chemotherapy-free combination therapy being developed by NOBO Medicine for the treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). The regimen combines poseltinib, an orally active, irreversible Bruton's tyrosine kinase (BTK) and TEC kinase inhibitor; lenalidomide, an immunomodulatory drug (IMiD) that binds to cereblon (CRBN) to promote the proteasomal degradation of transcription factors IKZF1 and IKZF3; and glofitamab, a CD20xCD3 T-cell engaging bispecific monoclonal antibody. This combination leverages the synergistic effects of BTK inhibition, immunomodulation, and T-cell-mediated cytotoxicity to target and eliminate malignant B cells. The regimen is currently being evaluated in a Phase II clinical trial.
- Other names
- GPLGPL regimenglofitamab + poseltinib + lenalidomideposeltinib + lenalidomide + glofitamab
02
Targets
CD20 (B-lymphocyte antigen CD20)CRBN (Cereblon)BTK (Bruton tyrosine kinase)TXKCD3 (T-cell surface glycoprotein CD3)BMX (Bone Marrow Tyrosine Kinase X-linked)
Beyond the preview
Go deeper on poseltinib + lenalidomide + glofitamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on poseltinib + lenalidomide + glofitamab.